News · News & Updates
Stay up to date with Poseidon's latest progress, research breakthroughs, product approvals and corporate news
Our 4th-generation EGFR inhibitor NVP-201 met its primary endpoint in the pivotal Phase III trial...
NMPA approved our novel cephalosporin antibiotic NVP-412 for complicated intra-abdominal infections...
We signed a strategic cooperation agreement with the Institute of Hematology, CAMS, to jointly develop gene therapies...
Our innovative GLP-1/GIP/Glucagon triple agonist NVP-305 dosed the first patient in its Phase II obesity trial...
Our PEGylated rhGH injection was approved for adult growth hormone deficiency...
Our CD19-targeted CAR-T NVP-508 presented latest Phase II data at the 65th ASH Annual Meeting...
Our 9-valent HPV vaccine was approved to expand its indication to males aged 9-45...
We signed a cooperation agreement with a leading dermatology hospital to conduct real-world studies...
Together with the Chinese Red Cross Foundation, we launched a national burn prevention program...